Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Novartis is building two new radioligand therapy (RLT) manufacturing facilities in the USA to enhance its supply chain for cancer treatments. This move supports the growing use of RLTs, a form of precision medicine that targets tumors with radiation. 6 September 2024
Belgium’s largest drugmaker UCB announced a strategic divestment deal in China, underscoring its strategic shift towards innovation and partnership in one of the world’s fastest-growing pharmaceutical markets. 27 August 2024
The UK’s largest pharma company AstraZeneca has rejected claims that it is moving its vaccine operations to the USA, according to media reports. 23 August 2024
Mitsubishi Tanabe Pharma announced the termination of its exclusive sales rights agreements with AnGes for the HGF gene therapy product, Collategene (beperminogene perplasmid) intramuscular injection targeting peripheral arterial diseases in Japan and the USA. 23 August 2024
UK pharma major AstraZeneca has become the only current UK-lis¬ted company to reach a £200 billion ($256.4 billion) valuation, the Financial Times reported today, noting that it is a vindication of the company’s bet on developing a leading portfolio of cancer drugs. 14 August 2024
US pharma giant Pfizer has announced the publication of real-world results from a cohort of the longitudinal, observational Phase IV THAOS (Transthyretin Amyloidosis Outcomes Survey) study in the Journal of Cardiac Failure. 8 August 2024
Japanese drugmaker Shionogi says that its New Drug Application (NDA) for cefiderocol has been accepted for review by the Center for Drug Evaluation, National Medical Products Administration (NMPA). 5 August 2024
Germany’s Bayer has submitted to the US Food and Drug Administration for approval to market elinzanetant for moderate to severe vasomotor symptoms (VMS), commonly known as hot flashes, associated with menopause. 2 August 2024
Spanish plasma-derived medicines company Grifols announced with the Andorran government the cancellation of the immunology research center planned for the parish of Ordino. 29 July 2024
The US Food and Drug Administration (FDA) approved Palforzia (peanut [Arachis hypogaea] allergen powder-dnfp] to include initiation of treatment, up-dosing and maintenance in individuals ages one through three years. 27 July 2024
Vividion Therapeutics, a wholly-owned subsidiary of Germany’s Bayer, today announced it will expand its global innovation capabilities with a new research and development (R&D) center and corporate headquarters in San Diego, California. 23 July 2024
US pharm major Eli Lilly on Friday revealed via a social media posting that it has been granted approval from the Chinese National Medical Products Administration (NMPA) to sell tirzepatide for weight loss in the country. 20 July 2024
The US Food and Drug Administration (FDA) issued a draft guidance for industry, “Pediatric Inflammatory Bowel Disease: Developing Drugs for Treatment,” to help sponsors in the clinical development of drugs to treat pediatric patients with inflammatory bowel disease (IBD). 19 July 2024
Global drugmakers operating in Russia will be able to label their drugs directly at customs warehouses in Russia, which will allow them to save on costs and facilitate imports of many of foreign drugs to the Russian market. 30 July 2020
Eli Lilly and Boehringer Ingelheim have announced positive top-line results from the EMPEROR-Reduced Phase III trial of Jardiance (empagliflozin). 30 July 2020
While revenues declined 2% to $5.4 billion, USA-based drugmaker Eli Lilly beat profit forecasts for the second quarter of 2020, the firm announced on Thursday. 30 July 2020
French drugmaker Ipsen today announced financial results for the first half of 2020, with the firm’s shares gaining 12.1% to 82.20 euros by early afternoon. 30 July 2020
Growing revenues and profitability in step with pipeline development, British drugmaker AstraZeneca posted an upbeat second quarter results statement on Thursday, with a strong focus on efforts to combat the novel coronavirus. 30 July 2020
The Phase III ADVANCE trial evaluating the investigational medicine atogepant, an orally-administered calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) met its primary endpoint of statistically significantly greater reduction in mean monthly migraine days, compared to placebo. 30 July 2020
A parliamentary committee has advised the government to create a parallel domestic supply chain for certain medicines to ensure the UK can cope with future health crises. 29 July 2020
The Franco-English pairing of Sanofi and GlaxoSmithKline have agreed with the UK government to supply up to 60 million doses of a COVID-19 vaccine. 29 July 2020
US biotech major Gilead Sciences says that Health Canada has issued a marketing authorization with conditions (Notice of Compliance with Conditions, or NOC/c) for Veklury (remdesivir). 29 July 2020
Despite second quarter sales being undercut by the coronavirus pandemic, French drugs and vaccines specialist Sanofi has raised its projection for the year, spurred by cost cutting measures and the sale of its stake in Regeneron Pharmaceuticals. 29 July 2020
At the end of 2019, the failure of a key Phase II test of poziotinib hollowed out shares in Nevada, USA-based oncology firm Spectrum Pharmaceuticals. 29 July 2020
GBA Group Pharma, a European service provider for pharma and biotech companies, has warned of risks to drugmakers’ clinical trial plans caused by Brexit. 28 July 2020
Chinese company Hutchison China MediTech, commonly-known as Chi-Med, and US pharma major Eli Lilly have amended their 2013 license and collaboration agreement on fruquintinib with Lilly Shanghai, an affiliate of Lilly. 28 July 2020
Positive top-line results from the Phase III DAPA-CKD trial will bring AstraZeneca’s diabetes med Farxiga (dapagliflozin) one step closer to a new indication in kidney failure. 28 July 2020
US biopharma firm Palatin Technologies has mutually terminated the January 2017 license agreement which granted AMAG Pharmaceuticals exclusive North American rights to market Vyleesi (bremelanotide). 27 July 2020
Swiss pharma giant Roche’s (ROG: SIX) Genentech unit has topped a survey featuring nine companies for corporate reputation in 2019, according to bleeding disorders patient groups. 27 July 2020
Early in the current White House administration, exceptionally strong rhetoric around drug pricing from US President Donald Trump rattled pharma markets, as investors feared new measures to control drug prices were imminent. 27 July 2020